![logo](/logos/ANAB.webp)
AnaptysBio, Inc.
NASDAQ:ANAB
35.9 (USD) • At close September 6, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | AnaptysBio, Inc. |
Symbool | ANAB |
Munteenheid | USD |
Prijs | 35.9 |
Beurswaarde | 1,084,172,820 |
Dividendpercentage | 0% |
52-weken bereik | 13.36 - 41.308 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Daniel R. Faga |
Website | https://www.anaptysbio.com |
An error occurred while fetching data.
Over AnaptysBio, Inc.
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)